Category News

SOTIO Expands ADC Pipeline with Two Bispecific Candidates, SOT112 and SOT113

SOTIO Expands ADC Pipeline with Two Bispecific Candidates, SOT112 and SOT113

SOTIO Expands ADC Pipeline with Bispecific Candidates SOT112 and SOT113 SOTIO Biotech Advances Two Promising Bispecific Antibody-Drug Conjugate Programs SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has announced an exciting development in its collaboration with Synaffix B.V.,…

Read MoreSOTIO Expands ADC Pipeline with Two Bispecific Candidates, SOT112 and SOT113

Baszucki Group Launches Two Research Initiatives for Youth with Bipolar Disorder

Baszucki Group Launches Two Initiatives Exploring Ketogenic Therapy for Youth with Bipolar Disorder Baszucki Group has announced the launch of two innovative research initiatives aimed at exploring the effectiveness of ketogenic therapy for children and adolescents with bipolar disorder. These…

Read MoreBaszucki Group Launches Two Research Initiatives for Youth with Bipolar Disorder
SCORPIO-PEP Phase 3 Ensitrelvir First Oral Antiviral to Prevent COVID-19

SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 as Post-Exposure Prophylaxis

Ensitrelvir Demonstrates Effectiveness in Preventing COVID-19 as Post-Exposure Prophylaxis: Results from the SCORPIO-PEP Phase 3 Trial SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 as Post-Exposure Prophylaxis At the Conference on Retroviruses and Opportunistic Infections 2025, Shionogi &…

Read MoreSCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 as Post-Exposure Prophylaxis
Oligomerix Publishes Preclinical Results of Oral Alzheimer's Drug Study

Oligomerix Publishes Preclinical Results of Oral Alzheimer’s Drug Study

Oligomerix Publishes Preclinical Results of Oral Alzheimer’s Drug Study Oligomerix, Inc., a pioneering clinical-stage biotechnology company focused on developing protein self-association inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, has announced the publication of a preclinical study demonstrating the…

Read MoreOligomerix Publishes Preclinical Results of Oral Alzheimer’s Drug Study
InTandem Capital Partners Invests in Clinilabs for Chemical Industry Growth

InTandem Capital Partners Invests in Clinilabs for Chemical Industry Growth

InTandem Capital Partners Invests in Clinilabs to Accelerate CNS Drug and Device Development InTandem Capital Partners, a private equity firm specializing in healthcare services, has announced a strategic partnership with Clinilabs, a global full-service contract research organization (CRO). This collaboration…

Read MoreInTandem Capital Partners Invests in Clinilabs for Chemical Industry Growth
IQVIA Named Leader in IDC MarketScape’s 2024 Decentralized Clinical Trial Assessment

IQVIA Named Leader in IDC MarketScape’s 2024 Decentralized Clinical Trial Assessment

IQVIA Recognized as a Leader in IDC MarketScape’s 2024 Assessment for Decentralized Clinical Trial Technologies and Consulting Services IQVIA, a global leader in AI-powered analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, has been…

Read MoreIQVIA Named Leader in IDC MarketScape’s 2024 Decentralized Clinical Trial Assessment
Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease

Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease

Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced that the first patient has been dosed in its Phase 2a clinical trial evaluating VENT-02 in patients with…

Read MoreVentus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease